Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non Operating Income: 2009-2024

Historic Non Operating Income for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $2.9 million.

  • Lineage Cell Therapeutics' Non Operating Income fell 3194.87% to -$26.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.3 million, marking a year-over-year decrease of 1763.82%. This contributed to the annual value of $2.9 million for FY2024, which is 99.59% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Non Operating Income stood at $2.9 million for FY2024, which was up 99.59% from $1.5 million recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Non Operating Income high stood at $5.9 million for FY2021, and its period low was -$3.3 million during FY2022.
  • For the 3-year period, Lineage Cell Therapeutics' Non Operating Income averaged around $351,667, with its median value being $1.5 million (2023).
  • In the last 5 years, Lineage Cell Therapeutics' Non Operating Income slumped by 155.41% in 2022 and then surged by 144.08% in 2023.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Non Operating Income stood at $4.5 million in 2020, then skyrocketed by 31.35% to $5.9 million in 2021, then plummeted by 155.41% to -$3.3 million in 2022, then skyrocketed by 144.08% to $1.5 million in 2023, then spiked by 99.59% to $2.9 million in 2024.